Reports Significant Revenue Growth and Gross Margin Expansion in 2025
2025 Financial Highlights Compared to 2024:
- Net revenue increased 216% to
$431,609 from$136,643 - Gross Margin Expanded by
7,240 Basis Points to 76.8% - Excluding a one-time, non-cash impairment charge of
$26.3 million , net loss from continuing operations improved by approximately$37,000 year-over-year - As of
December 31, 2025 , the company had cash and cash equivalents of approximately$6.7 million and positive working capital of approximately$5.2 million
Key Operational Highlights in 2025 and Subsequent Events:
- Secured multiple PBM-led GPO rebate agreements, supporting expanded commercial coverage and formulary placement for Arbli™
- Executed institutional GPO agreements, expanding
U.S. access to more than 2,500 healthcare institutions nationwide for Arbli™ - Achieved formulary inclusion with major national health plans for Arbli™, extending coverage to over 100 million lives
- Received an Orange Book-listable patent for Arbli™ (losartan potassium) Oral Suspension, 10mg/mL, the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market for treating hypertension, reinforcing and expanding Scienture’s intellectual property position
- Established a strategic collaboration with BlinkRx for Arbli™ to enhance patient access, fulfillment, and adherence through an integrated digital pharmacy and hub services platform
- Received an Orange Book-listable patent for REZENOPY™ (naloxone HCl) nasal spray 10 mg, the highest-dose FDA-approved naloxone HCl nasal spray for emergency opioid overdose treatment
- Formalized multiple commercial GPO agreements for REZENOPY™, expanding access to over 5,000 healthcare institutions and reaching approximately 60% of the
U.S. institutional market, including first responders, EMS providers, and rehabilitation centers
Management Commentary
“We believe 2026 will reflect the momentum we’ve built across prescriber adoption, distribution, and patient demand for Arbli™, while also positioning us for the planned commercial launch of REZENOPY™ in the second quarter of 2026,” stated
2025 Financial Summary
Revenue for the year ended
Total operating expenses were
As of
About Arbli™
Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
Arbli™ is the first and only oral liquid formulation of losartan approved by the
INDICATION
Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
- Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
IMPORTANT SAFETY INFORMATION
- Do not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
- Do not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli™ in patients with renal impairment (GFR <60 mL/min).
- Do not administer Arbli™ in patients with severe hepatic impairment. Arbli™ has not been studied in patients with severe hepatic impairment.
- The most common adverse reactions are (incidence =2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.
Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About Hypertension
Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the
About REZENOPY™
REZENOPY™ (naloxone HCl) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present.
REZENOPY™ nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray device.
IMPORTANT SAFETY INFORMATION
REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration as emergency therapy in settings where opioids may be present and is not a substitute for emergency medical care.
Important Safety Information
- Contraindications: REZENOPY™ nasal spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.
- Warnings and Precautions:
- Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance.
- Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
- Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid-dependent may precipitate opioid withdrawal. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for the development of opioid withdrawal.
- Risk of Cardiovascular Effects: Abrupt postoperative reversal of opioid depression may result in adverse cardiovascular effects. These events have primarily occurred in patients who had pre-existing cardiovascular disorders or received other drugs that may have similar adverse cardiovascular effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
- Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer additional doses as necessary while awaiting emergency medical assistance.
- Adverse Reactions: The following adverse reactions were observed in a REZENOPY™ nasal spray clinical study: upper abdominal pain, nasopharyngitis, and dysgeusia.
For complete product information, including Patient Information, please refer to the full Prescribing Information.
About
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the
Forward-looking statements speak only as of the date they are made.
Contact:
Phone: (866) 468-6535
Email: IR@Scienture.com
Consolidated Balance Sheets
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 6,662,008 | $ | 308,096 | ||||
| Accounts receivable, net | 731,328 | 11,106 | ||||||
| Inventory | 213,408 | - | ||||||
| Prepaid expenses | 262,278 | 4,560 | ||||||
| Notes receivable - related party | - | 1,300,000 | ||||||
| Other receivables | - | 4,138,770 | ||||||
| Deferred offering costs | 47,384 | 534,800 | ||||||
| Current assets of discontinued operations | - | 8,145 | ||||||
| Total current assets | 7,916,406 | 6,305,477 | ||||||
| Property, plant and equipment, net | 15,500 | 17,500 | ||||||
| Deposits | - | 22,039 | ||||||
| Notes receivable | 5,000,000 | - | ||||||
| Interest receivable | 250,000 | - | ||||||
| Intangible assets, net | 70,973,064 | 76,400,000 | ||||||
| - | 21,372,960 | |||||||
| Operating lease right-of-use assets | 23,360 | 201,433 | ||||||
| Deferred tax asset | - | 534,396 | ||||||
| Total assets | $ | 84,178,330 | $ | 104,853,805 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,443,266 | $ | 2,898,683 | ||||
| Accrued liabilities | 657,034 | 1,313,731 | ||||||
| Other current liabilities | - | 5,441 | ||||||
| Loan payable, related party | - | 415,000 | ||||||
| Convertible note, net of debt discount - current portion | - | 2,285,423 | ||||||
| Operating lease liability - current | 24,137 | 63,334 | ||||||
| Warrant liability | 10,914 | 919,935 | ||||||
| Development agreement liability - current portion | 600,000 | - | ||||||
| Current liabilities of discontinued operations | - | 5,346 | ||||||
| Total current liabilities | 2,735,351 | 7,906,893 | ||||||
| Convertible notes, net of debt discount | - | 612,275 | ||||||
| Derivative liability | - | 2,296,834 | ||||||
| Operating lease liability - net of current portion | - | 156,469 | ||||||
| Development agreement liability | 285,000 | 1,285,000 | ||||||
| Deferred tax liability | 11,037,595 | 13,524,213 | ||||||
| Total liabilities | 14,057,946 | 25,781,684 | ||||||
| Commitments and contingencies (Note 15) | ||||||||
| Stockholders’ equity (deficit): | ||||||||
| Series A preferred stock, | - | - | ||||||
| Series B preferred stock, | - | - | ||||||
| Series C preferred stock, | - | - | ||||||
| Series X preferred stock, | - | - | ||||||
| Common stock, | 406 | 87 | ||||||
| Additional paid-in capital | 150,671,215 | 118,111,007 | ||||||
| Accumulated deficit | (80,551,237 | ) | (39,038,973 | ) | ||||
| Total stockholders’ equity | 70,120,384 | 79,072,121 | ||||||
| Total liabilities and stockholders’ equity | $ | 84,178,330 | $ | 104,853,805 | ||||
Consolidated Statements of Operations
Years Ended
| Year Ended | ||||||||
| 2025 | 2024 | |||||||
| Revenues | $ | 431,609 | $ | 136,643 | ||||
| Cost of sales | 100,127 | 130,638 | ||||||
| Gross profit | 331,482 | 6,005 | ||||||
| Operating expenses: | ||||||||
| Wage and salary expense | 2,118,568 | 2,111,066 | ||||||
| Professional fees | 2,407,822 | 1,458,332 | ||||||
| Accounting and legal expense | 2,070,337 | 1,807,041 | ||||||
| Technology expense | 97,261 | 416,311 | ||||||
| General and administrative | 7,926,016 | 6,677,580 | ||||||
| Research and development | 1,956,270 | 2,236,690 | ||||||
| Impairment loss | 26,346,050 | - | ||||||
| Total operating expenses | 42,922,324 | 14,707,020 | ||||||
| Operating loss | (42,590,842 | ) | (14,701,015 | ) | ||||
| Non-operating income (expense): | ||||||||
| Change in fair value of warrant liability | 909,020 | (182,982 | ) | |||||
| Change in fair value of derivative liability | 2,296,834 | 180,383 | ||||||
| Impairment of investment | - | (2,500,000 | ) | |||||
| Loss on conversion of note payable | (53,446 | ) | - | |||||
| Loss on disposition of subsidiaries | (288,204 | ) | - | |||||
| Interest income | 302,702 | 135,337 | ||||||
| Loss on disposal of asset | - | (374,968 | ) | |||||
| Interest expense | (4,083,206 | ) | (1,335,631 | ) | ||||
| Total non-operating expense | (916,300 | ) | (4,077,861 | ) | ||||
| Net loss from continuing operations | (43,507,142 | ) | (18,778,876 | ) | ||||
| Benefit / (provision) for income taxes | 1,994,878 | 534,396 | ||||||
| Net loss from continuing operations, net of tax | (41,512,264 | ) | (18,244,480 | ) | ||||
| Net income from discontinued operations, net of tax | - | 27,310,278 | ||||||
| Net (loss) income | $ | (41,512,264 | ) | $ | 9,065,798 | |||
| Net loss per common share from continuing operations | ||||||||
| Basic | $ | (2.70 | ) | $ | (5.41 | ) | ||
| Diluted | $ | (2.70 | ) | $ | (5.41 | ) | ||
| Net income per common share from discontinued operations | ||||||||
| Basic | $ | - | $ | 8.09 | ||||
| Diluted | $ | - | $ | 7.47 | ||||
| Net (loss) income per common share | ||||||||
| Basic | $ | (2.70 | ) | $ | 2.69 | |||
| Diluted | $ | (2.70 | ) | $ | 2.48 | |||
| Weighted average common shares outstanding | ||||||||
| Basic | 15,347,312 | 3,375,325 | ||||||
| Diluted | 15,347,312 | 3,653,609 | ||||||
